ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Declaration of interests The Division of Radiation Oncology of the European Institute of Oncology IRCCS received research funding from the Italian Association for Cancer Research, Fondazione Istituto Europeo di Oncologia-Centro Cardiologico Monzino, Accuray, and Ion Beam applications. NF has received honoraria for consulting, an advisory role, speaker bureau, travel, or research grants from Merck Sharp & Dohme, Merck, Novartis, AstraZeneca, Roche, Menarini, Daiichi Sankyo, GSK, Gilead, Sysmex, Veracyte, Sakura, Leica Biosystems, Lilly, and Pfizer. These companies had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. BAJ-F received speakers fees from Bayer, Accuray, Astellas, IBA, Ipsen, AstraZeneca, Tecnologie avanzate, Recordati, and Novartis. BAJ-F participated in the advisory boards of Accuray, Bayer, and Seagen, all outside the current project. CT received travel support and honorarium from Boston Scientific, Diffusion Pharmaceuticals, and Vision RT. CT participated in advisory boards for Bayer, Telix, Lantheus, and Molli Surgical and receives royalties from Wolter Kluwer, all outside the current project. All other authors declare no competing interests. 10. Instr Course Lect. 2004;53:639-44. The biopsy. Scarborough MT(1). Author information: (1)Department of Orthopedic Surgery, University of Florida, Gainesville, Florida, USA. The biopsy of a musculoskeletal lesion is an important event, the outcome of which guides patient management and helps determine patient prognosis. The principles of biopsy include complete radiologic staging before the biopsy, thorough prebiopsy planning including consultation with the pathologist and radiologist, determining the most appropriate method of biopsy (fine needle, core needle, open surgical biopsy), placing the biopsy tract appropriately, and making sure the biopsy tract can be removed at the time of resection, avoiding contamination of uninvolved structures, avoiding transverse incisions, preventing pathologic fracture, handling biopsy tissue appropriately, and considering referral before biopsy. The common errors of biopsy include sampling errors, postbiopsy hematomas, the use of transverse incisions, tumor implantation, and the treatment of an unsuspected sarcoma with prophylactic fixation. Thoughtful prebiopsy planning and careful completion of the biopsy can result in an expedient and accurate diagnosis. If the treating physician lacks significant expertise in performing biopsy and management of patients with musculoskeletal lesions, then referral to a musculoskeletal oncologist before biopsy should be considered.